Main text
Initially, scientists coined the term “error catastrophe” to indicate the collective loss of genetic information in a specific organism’s lineage. It illustrates the proposed inability of a genomic element in a population due to the decrease in the conformity of its replication machinery beyond a certain threshold level.1,2 Scientists also proposed different mathematical models to illustrate the error catastrophe occasionally. Eigen and Schuster proposed one initial mathematical model for error catastrophe, and the model predicted through mathematics the high error rates due to the error catastrophe effect.1,3
An error catastrophe is noted over time when a high mutation rate occurs during viral replication. A high mutation frequency was observed in the RNA virus compared with the DNA virus, so scientists have described the error catastrophe of RNA virus from time to time. Crotty et al. illustrated a term to explain ribavirin’s antiviral strategy.4 Initially, error catastrophe was commenced in molecular evolution theory. Virologists more commonly used the term to describe the antiviral strategy. In this article, we endeavor to depict a model molecular mechanism of the error catastrophe in SARS-CoV-2 due to the administration of an antiviral drug named molnupiravir (Figure 1A). We explained that the error catastrophe phenomenon leads to lethal mutagenesis of the virus.
Figure 1.
A schematic diagram illustrates a model of error catastrophe and the mutagenic pathway of the antiviral therapeutic molecule molnupiravir against SARS-CoV-2
(A) A model of error catastrophe has been depicted to illustrate the mutagenic effect of molnupiravir on SARS-CoV-2. The model has been developed following the general model of error catastrophe described by Crotty et al.4 (B) An overall schematic diagram explained the molecular mechanisms of molnupiravir against SARS-CoV-2. (C) Another schematic diagram depicted the incorporation of NHC-TP in the SARS-CoV-2 genome.
Even if vaccination campaigns have reduced the impact of COVID-19 to some extent, the continued destruction brought on by the SARS-CoV-2 virus has had a catastrophic impact on many communities worldwide. Moreover, SARS-CoV-2 will probably establish itself as a prevalent and ongoing presence, resulting in the rise of strains that can resist vaccines and emphasizing the necessity to create therapeutic molecules that target the virus.5 The RNA-dependent RNA polymerase of SARS-CoV-2 plays a significant role in ongoing drug development endeavors to combat COVID-19. Molnupiravir is an antiviral medication with a wide range of effectiveness against various viruses. It is taken orally and is a modified form of a nucleoside analog called β-D-N4-hydroxycytidine (NHC). When molnupiravir or NHC is present during the replication process of coronaviruses, it can lead to an increased occurrence of specific genetic mutations. These mutations involve the conversion of nucleotides G to A and C to U. These heightened mutation rates have been associated with more potent antiviral properties.6 It is presently going through phase 2/3 clinical studies. Through a mechanism known as “ethal mutagenesis”, it works to prevent virus replication (Figure 1B).7
Besides SARS-CoV-2, molnupiravir is a versatile antiviral substance that can hinder the replication of a plethora of viruses, namely the chikungunya virus, norovirus, respiratory syncytial virus, ebola virus, etc., in cellular environments.8 The NHC’s triphosphorylated derivative acts as a viral RNA polymerase substrate and hampers viral replication. Molnupiravir demonstrated significant effectiveness in inhibiting the replication of SARS-CoV-2 in laboratory tests, with an EC50 value falling within the submicromolar range.8,9 The suppressive impact was also seen in animal experiments involving Syrian hamsters and mice modified to have human characteristics.10,11 Furthermore, when NHC was administered to infected ferrets, it prevented the transmission of SARS-CoV-2 to animals that were not treated and remained uninfected.12 NHC undergoes cleavage in the plasma as it enters the cell.13 Then, host kinases phosphorylate it, converting the NHC into NHC-5′-triphosphate (NHC-TP), the active form. After that, NHC-TP is integrated by RdRp, replacing the uridine or cysteine residue, into the newly generated minus-gRNA and sub-genomic RNA (Figure 1C).
Interestingly, the NHC-TP molecule faces more competition for integration from C than from U. As a result, the triphosphate molecule that contains minus-gRNA serves as the template, which is essential for the synthesis of positively charged gRNA and a positive-strand sub-genomic messenger RNA. The positive-strand RNA products are mutated due to this process, and non-functional viruses are also produced.14 Since NHC exists in two distinct tautomeric forms, putting NHC-TP in the template can form a base pair with either adenine or guanine. NHC mimics C and creates three hydrogen bonds with G in its hydroxylamine or amino form. However, when NHC is in its imino or oxime form, that mimics U and creates two hydrogen bonds with A.15,16
In-depth biochemical analyses and high-resolution cryo-EM structures were used by Kabinger et al. to analyze the effects of molnupiravir on the RdRp’s active site. According to their research, the RdRp’s active site can template A or G with molnupiravir without seriously disrupting the area or the nucleic acid scaffold.14 During a limited time of therapy and monitoring, the molnupiravir phase 1 clinical trial, conducted on healthy volunteers, demonstrated favorable tolerability and no detectable side effects.17 Most of the understanding of how it works comes from experiments conducted on cell cultures. While remdesivir stops RNA synthesis, molnupiravir appears to function as a mutagen.8,11,18,19,20 In late 2021, molnupiravir received authorization in both the United Kingdom and the United States, with numerous other countries approving it.21 In a recent clinical research on molnupiravir, it was discovered that using molnupiravir within the first 5 days of symptom onset reduced hospitalization by 30% in patients with symptomatic SARS-CoV-2 infection and risk of severe disease.22 Based on these findings, the US Food and Drug Administration have authorized molnupiravir to treat symptomatic SARS-CoV-2 infection.23
Lethal mutagenesis is an all-encompassing strategy to attack different RNA viruses by capitalizing on their propensity to evolve often and their constrained capacity to tolerate alterations. Different mutagenic nucleosides have been used to successfully eradicate viruses in cell cultures on numerous occasions.24 According to a recent study by Zhou et al., NHC is almost 100 times more effective than ribavirin and favipiravir for treating SARS-CoV-2. The study also found a correlation between increased NHC activity and a higher frequency of viral RNA alterations.25 Three mutagenic ribonucleoside/base analogs were compared to determine the antiviral and mutagenic effects of SARS-CoV-2. According to the findings, rNHC was highly antiviral and mutagenic against SARS-CoV-2 at doses as low as 0.3 μM.
On the other hand, favipiravir proved to be a lethal antiviral through mutagenesis.26 However, the concentration of therapeutic molecules is an essential factor. The modest antiviral activity began at a concentration of 100 μM and did not show any discernible mutagenic activity up to a concentration of 300 μM. Alternatively, given the same mutagenic effects, ribavirin displayed mutagenic activity at a concentration 300 times greater than rNHC.25 Mutagenic ribonucleoside analogs have a specific way of functioning, which involves being processed by the host cell through ribonucleotide reductase, converting them to the 2′-deoxyribonucleotide form. These converted analogs can then become part of the DNA, causing mutations in the host organism. For an elucidative investigation, an experiment was also performed using a modified hypoxanthine phosphoribosyltransferase (HPRT) gene mutation assay to evaluate mutagenesis in the host DNA.27 Zhou et al. also indicated that rNHC exhibits potent antiviral activity that surpasses favipiravir and ribavirin. However, it is essential to note that NHC also demonstrates mutagenic effects on the host, as observed in the HPRT mutagenesis assay.25
Due to the distinct mechanism of action of molnupiravir, it has become a promising therapeutic approach against SARS-CoV-2 and other RNA viruses. It causes a high mutation rate during viral replication by attacking the viral RNA polymerase, which results in an error catastrophe. This process exhausts the virus’s capacity for precise replication, leading to the buildup of deadly mutations and lethal mutagenesis. Finally, it causes the eventual extinction of the viral population. This method takes advantage of the RNA viruses' innate susceptibility to high mutation rates and offers a potential treatment option for RNA viral infections. Understanding and utilizing molnupiravir’s therapeutic potential in treating viral illnesses will require additional studies and clinical trials.
Data availability
The authors confirm that the data supporting the findings of this study are available within the article.
References
- 1.Summers J., Litwin S. Examining the theory of error catastrophe. J. Virol. 2006;80:20–26. doi: 10.1128/JVI.80.1.20-26.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Eigen M. Error catastrophe and antiviral strategy. Proc. Natl. Acad. Sci. USA. 2002;99:13374–13376. doi: 10.1073/pnas.212514799. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Eigen M., Schuster P. The hypercycle. A principle of natural self-organization. Part A: emergence of the hypercycle. Naturwissenschaften. 1977;64:541–565. doi: 10.1007/BF00450633. [DOI] [PubMed] [Google Scholar]
- 4.Crotty S., Cameron C.E., Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. USA. 2001;98:6895–6900. doi: 10.1073/pnas.111085598. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Hall M.D., Anderson J.M., Anderson A., Baker D., Bradner J., Brimacombe K.R., Campbell E.A., Corbett K.S., Carter K., Cherry S., et al. Report of the national institutes of health SARS-CoV-2 antiviral therapeutics summit. J. Infect. Dis. 2021;224:S1–S21. doi: 10.1093/infdis/jiab305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Gordon C.J., Tchesnokov E.P., Schinazi R.F., Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J. Biol. Chem. 2021;297:100770. doi: 10.1016/j.jbc.2021.100770. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Malone B., Campbell E.A. Publisher correction: molnupiravir: coding for catastrophe. Nat. Struct. Mol. Biol. 2021;28:955. doi: 10.1038/s41594-021-00683-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Agostini M.L., Pruijssers A.J., Chappell J.D., Gribble J., Lu X., Andres E.L., Bluemling G.R., Lockwood M.A., Sheahan T.P., Sims A.C., et al. Small-molecule antiviral beta-d-N(4)-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol. 2019;93:013488-19. doi: 10.1128/JVI.01348-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Zhao J., Guo S., Yi D., Li Q., Ma L., Zhang Y., Wang J., Li X., Guo F., Lin R., et al. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. Antivir. Res. 2021;190:105078. doi: 10.1016/j.antiviral.2021.105078. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Rosenke K., Hansen F., Schwarz B., Feldmann F., Haddock E., Rosenke R., Barbian K., Meade-White K., Okumura A., Leventhal S., et al. Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat. Commun. 2021;12:2295. doi: 10.1038/s41467-021-22580-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Sheahan T.P., Sims A.C., Zhou S., Graham R.L., Pruijssers A.J., Agostini M.L., Leist S.R., Schäfer A., Dinnon K.H., 3rd, Stevens L.J., et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 2020;12:eabb5883. doi: 10.1126/scitranslmed.abb5883. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Cox R.M., Wolf J.D., Plemper R.K. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat. Microbiol. 2021;6:11–18. doi: 10.1038/s41564-020-00835-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ehteshami M., Tao S., Zandi K., Hsiao H.M., Jiang Y., Hammond E., Amblard F., Russell O.O., Merits A., Schinazi R.F. Characterization of beta-d-N(4)-hydroxycytidine as a novel inhibitor of Chikungunya virus. Antimicrob. Agents Chemother. 2017;61:023955-16. doi: 10.1128/AAC.02395-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Kabinger F., Stiller C., Schmitzová J., Dienemann C., Kokic G., Hillen H.S., Höbartner C., Cramer P. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 2021;28:740–746. doi: 10.1038/s41594-021-00651-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Jena N.R. Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19. Phys. Chem. Chem. Phys. 2020;22:28115–28122. doi: 10.1039/d0cp05297c. [DOI] [PubMed] [Google Scholar]
- 16.Traut T.W. Physiological concentrations of purines and pyrimidines. Mol. Cell. Biochem. 1994;140:1–22. doi: 10.1007/BF00928361. [DOI] [PubMed] [Google Scholar]
- 17.Painter W.P., Holman W., Bush J.A., Almazedi F., Malik H., Eraut N., Morin M.J., Szewczyk L.J., Painter G.R. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob. Agents Chemother. 2021;65:024288-20. doi: 10.1128/AAC.02428-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Yoon J.J., Toots M., Lee S., Lee M.E., Ludeke B., Luczo J.M., Ganti K., Cox R.M., Sticher Z.M., Edpuganti V., Mitchell D.G. Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob. Agents Chemother. 2018;62:007666-18. doi: 10.1128/AAC.00766-18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Toots M., Yoon J.J., Cox R.M., Hart M., Sticher Z.M., Makhsous N., Plesker R., Barrena A.H., Reddy P.G., Mitchell D.G., et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 2019;11:eaax5866. doi: 10.1126/scitranslmed.aax5866. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Saha A., Sharma A.R., Bhattacharya M., Sharma G., Lee S.S., Chakraborty C. Probable molecular mechanism of remdesivir for the treatment of COVID-19: need to know more. Arch. Med. Res. 2020;51:585–586. doi: 10.1016/j.arcmed.2020.05.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Service R.F. Could a popular antiviral supercharge the pandemic? Science. 2023;379:526. doi: 10.1126/science.adh0582. [DOI] [PubMed] [Google Scholar]
- 22.Jayk Bernal A., Gomes da Silva M.M., Musungaie D.B., Kovalchuk E., Gonzalez A., Delos Reyes V., Martín-Quirós A., Caraco Y., Williams-Diaz A., Brown M.L., et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N. Engl. J. Med. 2022;386:509–520. doi: 10.1056/NEJMoa2116044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Swanstrom R., Schinazi R.F. Lethal mutagenesis as an antiviral strategy. Science. 2022;375:497–498. doi: 10.1126/science.abn0048. [DOI] [PubMed] [Google Scholar]
- 24.Perales C., Gallego I., de Ávila A.I., Soria M.E., Gregori J., Quer J., Domingo E. The increasing impact of lethal mutagenesis of viruses. Future Med. Chem. 2019;11:1645–1657. doi: 10.4155/fmc-2018-0457. [DOI] [PubMed] [Google Scholar]
- 25.Zhou S., Hill C.S., Sarkar S., Tse L.V., Woodburn B.M.D., Schinazi R.F., Sheahan T.P., Baric R.S., Heise M.T., Swanstrom R. beta-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J. Infect. Dis. 2021;224:415–419. doi: 10.1093/infdis/jiab247. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Chakraborty C., Bhattacharya M., Saha A., Alshammari A., Alharbi M., Saikumar G., Pal S., Dhama K., Lee S.S. Revealing the structural and molecular interaction landscape of the favipiravir-RTP and SARS-CoV-2 RdRp complex through integrative bioinformatics: insights for developing potent drugs targeting SARS-CoV-2 and other viruses. J. Infect. Public Health. 2023;16:1048–1056. doi: 10.1016/j.jiph.2023.05.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Johnson G.E. Mammalian cell HPRT gene mutation assay: test methods. Methods Mol. Biol. 2012;817:55–67. doi: 10.1007/978-1-61779-421-6_4. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The authors confirm that the data supporting the findings of this study are available within the article.

